The purpose of this study is to evaluate the safety and efficacy of nano drug（Gemzar® mix with Compound Glycyrrhizin Injection） interventional therapy using digital subtraction angiography（DSA） for liver cancer.
By enrolling patients with liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for liver cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection. The nano drug's size is detected by laser diffraction particle size analyzer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
Number of participants with Adverse events
Time frame: 1 year
Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
Time frame: 1 year
Progress free disease (PFS)
Time frame: 1 year
Overall survival (OS)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.